Bsc
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
No data
Clinical
Clinical Trials
155 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Recurrence | D012008 | — | — | — | — | 1 | 1 | — | 2 |
| Glioblastoma | D005909 | EFO_0000515 | — | — | — | 1 | 1 | — | 2 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Carcinoma | D002277 | — | C80.0 | — | 5 | 13 | — | 2 | 20 |
| Hepatocellular carcinoma | D006528 | — | C22.0 | — | 5 | 9 | — | 1 | 15 |
| Colorectal neoplasms | D015179 | — | — | — | 6 | 12 | — | — | 15 |
| Liver neoplasms | D008113 | EFO_1001513 | C22.0 | — | 4 | 9 | — | 1 | 14 |
| Non-small-cell lung carcinoma | D002289 | — | — | — | 6 | 8 | — | 1 | 14 |
| Lung neoplasms | D008175 | HP_0100526 | C34.90 | — | 5 | 9 | — | — | 13 |
| Syndrome | D013577 | — | — | — | 6 | 8 | — | — | 12 |
| Leukemia | D007938 | — | C95 | — | 3 | 7 | — | — | 10 |
| Myelodysplastic syndromes | D009190 | — | D46 | — | 5 | 7 | — | — | 10 |
| Preleukemia | D011289 | — | — | — | 4 | 7 | — | — | 9 |
Show 48 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Osteosarcoma | D012516 | — | — | — | 2 | — | — | — | 2 |
| Ovarian neoplasms | D010051 | EFO_0003893 | C56 | — | 1 | — | — | — | 1 |
| Ovarian epithelial carcinoma | D000077216 | — | — | — | 1 | — | — | — | 1 |
| Hypersensitivity | D006967 | HP_0012393 | T78.40 | — | 1 | — | — | — | 1 |
| Esophageal squamous cell carcinoma | D000077277 | — | — | — | 1 | — | — | — | 1 |
| Cytokine release syndrome | D000080424 | — | D89.83 | — | 1 | — | — | — | 1 |
| Islet cell adenoma | D007516 | EFO_0007331 | D13.7 | — | 1 | — | — | — | 1 |
| Urologic neoplasms | D014571 | — | C64-C68 | — | 1 | — | — | — | 1 |
| Transitional cell carcinoma | D002295 | — | — | — | 1 | — | — | — | 1 |
| Primary myelofibrosis | D055728 | — | D47.4 | — | 1 | — | — | — | 1 |
Show 13 more
Indications Phases 1
No data
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Chronic pain | D059350 | HP_0012532 | — | — | — | — | — | 4 | 4 |
| Prolapse | D011391 | — | — | — | — | — | — | 3 | 3 |
| Cardiovascular diseases | D002318 | HP_0001626 | — | — | — | — | — | 2 | 2 |
| Atherosclerosis | D050197 | EFO_0003914 | I25.1 | — | — | — | — | 2 | 2 |
| Heart failure | D006333 | HP_0001635 | I50 | — | — | — | — | 2 | 2 |
| Infections | D007239 | EFO_0000544 | — | — | — | — | — | 2 | 2 |
| Communicable diseases | D003141 | — | — | — | — | — | — | 2 | 2 |
| Peripheral arterial disease | D058729 | EFO_0004265 | — | — | — | — | — | 1 | 1 |
| Peripheral vascular diseases | D016491 | EFO_0003875 | I73.9 | — | — | — | — | 1 | 1 |
| Sleep apnea syndromes | D012891 | HP_0010535 | G47.3 | — | — | — | — | 1 | 1 |
Show 28 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | — |
| INN | — |
| Description | — |
| Classification | — |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | — |
| RxCUI | — |
| ChEMBL ID | — |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | — |
| UNII ID | — |
Target
No data
Variants
No data
Financial
No data
Trends
No data
Safety
Black-box Warning
No Black-box warning
Adverse Events
0 adverse events reported
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use